AI Momentum and Cancer Breakthroughs Fuel Stocks to New Highs

Nebius Group (NBIS), Cisco Systems (CSCO), and Sellas Life Sciences Group (SLS) hit fresh 52-week highs on May 13, with investors rewarding progress in AI infrastructure and drug development.

Nebius reported a 654% year-on-year jump in its Q1 revenue to $399 million, exceeding Wall Street estimates. The company also sharply increased its 2026 annual recurring revenue (ARR) outlook to $7 billion to $9 billion.

Cisco Systems' stock rallied after the networking giant raised its forecast for AI-related infrastructure orders to approximately $9 billion this fiscal year, up from $5 billion. This move is part of Cisco's shift towards AI-focused networking hardware and silicon development, which includes around 4,000 job cuts.

Sellas Life Sciences advanced its leukemia trials, with key Phase 3 results nearing for its Galinpepimut-S treatment. The company also reported higher cash reserves, with over $107 million to fund its studies.